The oral Janus kinase (JAK) inhibitor baricitinib is more effective than placebo or adalimumab (Humira) among RA patients with an inadequate response to methotrexate, a phase III trial shows. Results from the double-blind placebo and active controlled RA-BEAM study published in this week’s New England Journal of Medicine revealed that the trial’s primary efficacy end ...
Oral JAK inhibitor more effective than placebo or adalimumab: RA-BEAM
By Mardi Chapman with Nicola Garrett
16 Feb 2017